ArticleAnnals of medicine2025
The mortality of chronic kidney disease in Chinese subjects: a 12-year cohort based on clinical data in electronic health record.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health problem with increasing prevalence. The objective of this study was to investigate the CKD mortality rate in a large cohort study based on electronic health record (EHR).
methodsThis was a retrospective cohort based on Hospital's EHR. The follow-up period was from January 2008 to December 2019. We used demographics, laboratory tests, comorbidities and mortality information to do the analysis. The mortality data was gained from the Chinese Center for Disease Control and Prevention (CDC) database. Then the data was analyzed in the whole participants and subgroups.
results82,684 CKD patients were identified in final cohort. Overall, there were 10,454 patients who died during the 12-year follow-up. The crude mortality rate was 12.6% (2.4 per 100 patient-years). In CKD stages 4-5, the mortality rate significantly increased (10.2 and 8.8 per 100 patient-years, respectively). The major causes of death including cardiovascular diseases, infections and cancer. In the advanced (stages 4-5) CKD, the proportion of deaths caused by cancer significantly decreased (15-26% to 9-10%), while the proportion of deaths caused by renal failure markedly increased (2
conclusionIn conclusion, among the 82,684 CKD patients, the mortality rate was 2.4 per 100 patient-years. For advanced CKD patients, the mortality rate was significantly increased. As CKD progressed, deaths caused by cancer significantly decreased, while death caused by renal failure remarkably increased. Meanwhile, there may be a competing risk of all-cause mortality and progression to ESKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.